Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Multiple Sclerosis; Sclerosis | Phase 1/Phase 2 | ClinicalTrials |
| Diabetes Mellitus, Type 2; Insulin Resistance; Metabolic Syndrome | Phase 1/Phase 2 | ClinicalTrials |
| Alzheimer Disease | Phase 3 | ClinicalTrials |
| Fetal Growth Retardation | Phase 2 | ClinicalTrials |
| Cognitive Dysfunction; Memory Disorders | Phase 3 | ClinicalTrials |
| Breast Neoplasms; Neurotoxicity Syndromes | Phase 3 | ClinicalTrials |
| Alzheimer Disease; Cognition Disorders | Phase 4 | ClinicalTrials |
| Multiple Sclerosis; Sclerosis | Phase 2 | ClinicalTrials |
| Sexual Dysfunctions, Psychological | Phase 2 | ClinicalTrials |
| Cognitive Dysfunction | Phase 4 | ClinicalTrials |
| Glaucoma; Glaucoma, Open-Angle | Phase 2 | ClinicalTrials |
| Neuritis; Vestibular Neuronitis | Phase 3 | ClinicalTrials |
CONTENTS